2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow IMO-2055: new trials by email Literature Review of IMO-2055 trials Research Report on IMO-2055
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cetuximab, EMD 1201081 - Squamous Cell Carcinoma of the Head and Neck Cancer | Phase 2 | Completed | EMD Serono | 107 | 2009-12-01 | 2017-01-30 |
| Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma IMO-2055 - Renal Cell Carcinoma | Phase 2 | Completed | Idera Pharmaceuticals, Inc. | 92 | 2004-06-01 | 2018-06-12 |
Recurrence (2) · Carcinoma, Renal Cell (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1)
EMD Serono (1) · Idera Pharmaceuticals, Inc. (1)
United States (2) · Belgium (1) · Czechia (1) · France (1) · Hungary (1) · Poland (1) · Slovakia (1) · United Kingdom (1)
Alice Bexon, MD (1) · Philip Breitfeld, MD (1)